跳到主要內容

臺灣博碩士論文加值系統

(35.153.100.128) 您好!臺灣時間:2022/01/22 08:05
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:陳建文
研究生(外文):Chien-Wen Chen
論文名稱:不同形式維生素B6對血小板膜GPIIb/IIIa接受器結合度與抗血小板凝集研究
論文名稱(外文):Study on the antiplatelet aggregation of B6 vitamers by the occupancy of GPIIb/IIIa receptor
指導教授:張素瓊張素瓊引用關係
指導教授(外文):Sue-Joan Chang
學位類別:碩士
校院名稱:國立成功大學
系所名稱:生物學系
學門:生命科學學門
學類:生物學類
論文種類:學術論文
論文出版年:2002
畢業學年度:90
語文別:中文
論文頁數:89
中文關鍵詞:GPIIb/IIIa接受器維生素B6親和力凝集反應結合
外文關鍵詞:GPIIb/IIIa receptorB6 vitamersaffinityaggregationoccupancy
相關次數:
  • 被引用被引用:2
  • 點閱點閱:298
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
維生素B6的輔酉每 形式,磷酸比哆醛(pyridoxal-5-phosphate, PLP),在體內與體外系統均被發現具有抑制動物或人的血小板凝集作用。本研究室研究發現,PLP可與血小板膜上GPIIb/IIIa接受器結合而抑制纖維蛋白原(fibrinogen)與GPIIb/IIIa的結合。然而,PLP與GPIIb/IIIa結合對血小板凝集的影響則未知,因此,本研究利用流式細胞儀來直接定量血小板上GPIIb/IIIa接受器與不同濃度之四種維生素B6 (PN,PL,PLP,PM)結合的動力學,並探討不同濃度、不同型式之維生素B6對血小板膜蛋白GPIIb/IIIa的結合及其與血小板凝集之關係。
結果顯示,四種維生素B6 (PLP、PL、PN、PM)均會與GPIIb、GPIIIa或GPIIb/IIIa結合。未經四種維生素B6處理之血小板,抗體所標定到的GPIIb、GPIIIa、GPIIb/IIIa接受器分別約為6~8、4~5、12~14萬個。PLP、PL、PN、PM與GPIIb結合的解離常數(Kd, dissociation constant)分別為1.44 ±0.45、31.82 ±17.39、3.27 ±1.55、10.67 ±2.30 mM,與GPIIIa分別為1.36 ±0.61、4.47 ±2.58、2.85 ±1.43、6.02 ±2.36 mM,與GPIIb/IIIa分別為1.83 ±1.15、19.43 ±7.86、3.63 ±1.67、10.89 ±2.93 mM。
PLP與GPIIb的結合在≧0.6 mM為劑量依賴性(dose-dependent);IC50﹦1.59 ±0.24 mM,且在3 mM 時達最大結合。PLP與GPIIIa及GPIIb/IIIa complex的結合在1.8 mM時有閾值限制,即PLP≧1.8 mM時可顯著與GPIIIa及GPIIb/IIIa complex結合。PL與GPIIb、GPIIb/IIIa complex的結合在≧6 mM時為劑量依賴性;IC50分別為11.76 ±0.50 mM及5.85 ±0.20 mM,且在30 mM時達最大結合。PL與GPIIIa的結合在1.8 mM時有閾值限制。PN與GPIIb、GPIIIa及GPIIb/IIIa complex的結合在3 mM時有閾值限制。PM與GPIIb、GPIIb/IIIa complex的結合為劑量依賴性;IC50分別為28.14 ±15.84 mM及28.94 ±3.36 mM,且在30 mM 時達最大結合。但對GPIIIa結合6 mM時有閾值限制。
不同濃度PLP、PL、PN及PM處理下,四種維生素B6結合GPIIb、GPIIIa、GPIIb/IIIa與血小板凝集反應均呈負相關(r=-0.83~-0.94,P<0.000001),顯示隨著維生素B6與GPIIb/IIIa結合越多,血小板凝集越少。
本研究結論,由動力學顯示四種維生素B6對GPIIb及GPIIb/GPIIIa親和力(Kd)為PLP>PN>PM>PL,對GPIIIa親和力為PLP>PN>PL>PM。四種維生素B6與GPIIb、GPIIIa、GPIIb/IIIa接受器結合亦呈現相同結果。由此推測四種維生素B6抑制血小板凝集的能力為PLP>PN>PM>PL。由IC50與閾值亦顯示四種維生素B6抑制血小板凝集的能力為PLP>PN>PM>PL。

VitaminB6, in the coenzyme form of pyriodoxal-5-phosphate (PLP), has been found to inhibit in vitro and in vivo animal and human platelet aggregation. Studies in our laboratory indicated that PLP could bind to GPIIb/IIIa receptor leading to the prevention of fibrinogen binding to GPIIb/IIIa. However, the occupancy of GPIIb/IIIa by PLP in relation to the platelet aggregation is still unknown. Therefore, this study was carried out to quantify GPIIb/IIIa binding in platelets treated with various dose and forms of B6 vitamers (PLP; pyridoxal, PL; pyridoxine, PN; pyridoxamine, PM), using antibody-base assay, by flow cytometry. The antibody-binding was compared with inhibition of platelet aggregation.
The results showed that GPIIb, GPIIIa and GPIIb/IIIa complex were occupied by all tested B6 vitamers (PLP, PL, PN, PM). Antibodies identified 60000~80000、40000~60000、120000~140000 GPIIb, GPIIIa and GPIIb/IIIa complex sites per intact platelet, respectively. PLP, PL, PN and PM bound to GPIIb with dissociation constant (Kds) of 1.44 ±0.45、31.82 ±17.39、3.27 ±1.55、10.67 ±2.30 mM, respectively. PLP, PL, PN and PM bound to GPIIIa with Kds of 1.36 ±0.61、4.47 ±2.58、2.85 ±1.43、6.02 ±2.36 mM, respectively. PLP, PL, PN and PM bound to GPIIb/IIIa with Kds of 1.83 ±1.15、19.43 ±7.86、3.63 ±1.67、10.89 ±2.93 mM, respectively.
PLP bound to GPIIb in a dose-dependent and saturable manner (IC50, 1.59 ±0.24 mM), and maximum binding occurred at 3 mM. The threshold of PLP bound to GPIIIa and GPIIb/IIIa was 1.8 mM that PLP significant bound to GPIIIa and GPIIb/IIIa at 1.8 mM. When PL≧ 6 mM, PL bound to GPIIb and GPIIb/IIIa in a dose-dependent and saturable manner (IC50, 11.76 ±0.5 mM and 5.85 ±0.2 mM, respectively ), and maximum binding occurred at 30 mM. The threshold of PL bound to GPIIIa was 1.8 mM. The threshold of PN bound to GPIIb, GPIIIa and GPIIb/IIIa were 3 mM. PM bound to GPIIb and GPIIb/IIIa in a dose-dependent and saturable manner (IC50, 28.14 ±15.84 mM and 28.94 ±3.36 mM, respectively ), and maximum binding occurred at 30 mM. The threshold of PM bound to GPIIIa was 6 mM.
Occupancy of receptors by four B6 vitamers was negatively correlated with the platelet aggregation (r=-0.83~-0.94, P<0.000001) indicating the decreased platelet aggregation resulting from the binding of B6 vitamers to GPIIb/IIIa receptor.
In conclusion, the affinity of B6 vitamers for GPIIb, GPIIIa and GPIIb/IIIa complex were PLP>PN>PM>PL, PLP>PN>PL>PM and PLP>PN>PM>PL, respectively. We suggested that the potency of B6 vitamers against platelet aggregation were PLP>PN>PM>PL. The IC50 values and threshold also showed that the potency of B6 vitamers against platelet aggregation were PLP>PN>PM>PL.

目錄
頁數
中文摘要 I
英文摘要 IV
誌謝 V
目錄 VI
表目錄 VII
圖目錄 VIII
第一章:前言 1
第二章:文獻探討 3
第三章:研究動機與目的 14
第四章:材料及方法 16
第五章:結果 27
第六章:討論 36
第七章:參考文獻 40
表 53
圖 55
自述 89

1. Cox D, Aoki, Seki J, Motoyama Y, Yoshida K. The pharmacology of the integrins. Med Res Rev 1994; 14:195-228.
2. Ginsberg MH, Xiaoping D, O'Toole TE. Platelet integrins. Thromb Haemost 1993; 70:87-93.
3. Packham MA, Lam SC and Mustard JF. Vitamin B6 as an antithrombotic agent. Lancet. 1981; 2: 809-810.
4. Anonymous. Is vitamin B6 an antithrombotic agent ? Lancet. 1981; 1: 1299-1300.
5. Harker LA, Schwartz SM and Ross R. Endothelium and arteriosclerosis. Clinics in Haematology. 1981; 10: 283-296.
6. 黃秀雯,磷酸比哆醛抑制ADP誘發性血小板凝集機制之研究,國立成功大學生物學研究所碩士論文,中華民國八十八年六月。
7. Kieffer N, Phillips DR. Platelet membrane glycoproteins: function in cellular interactions. Annu Rev Cell Biol 1990; 6:329-357.
8. Hynes RO. Integrins: a family of cell surface receptors. Cell. 1987; 48: 549-554.
9. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992; 69: 11-25.
10. Frojmovic M, Wong T, van de Ven T. Dynamic measurements of the platelet membrane glyco protein IIb-IIIa receptor for fibrinogen by flow cytometry. Biophy J. 1991; 59: 815-827
11. Jennings LK, Phillips DR. Purification of glycoproteins IIb and IIIa from human platelet plasma membrane and characterization of a calcium-depend glycoprotein IIb-IIIa complex. J. Biol. Chem. 1982; 257:10458-10466.
12. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J. Clin. Invest. 1979; 64: 1393-1401
13. Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J. Biol. Chem. 1979; 254: 5357-5363
14. Sanchez-Mateos P, Cabanas C, Sanchez-Madrid F Semin F. Regulation of integrin function. Cancer Biol. 1996; 7: 99-109
15. Savage B, Ruggeri Z. Selective recognition of adhesive sites in surface-bound fibrinogen by glycoprotein IIb-IIIa on nonactivated platelets. J. Biol. Chem. 1991; 266: 11227-11233
16. Sims PJ, Ginsberg MH, Plow EF, Shattil SJ. Effect of platelet activation on the conformation of the plasma membrane glycoprotein IIb-IIIa complex. J. Biol. Chem. 1991; 266: 7345-7352
17. Van Willigen G. Akkerman JW. Regulation of glycoprotein IIb/IIIa exposure on platelets stimulated with alpha-thrombin. Blood 1992; 79: 82-90.
18. Ginsberg MH, Loftus JC, Plow EF. Cytoadhesions, integrins and platelets. Thromb Haemost 1988; 59: 1-6.
19. Peerschke EIB. Reversible and irreversible binding of fibrinogen to platelets. Platelets 1997; 8: 311-317.
20. Bennett JS, Zigmond S, Vilaire G, Cunningham ME and Bednar B. The platelet cytoskeleton regulates the affinity of the integrin αIIbβ3 for fibrinogen. J. Biol. Chem. 1999; 274: 25301-25307
21. Van Willigen G, Akkerman JW. Protein kinase C and cyclic AMP regulate reversible exposure of binding sites for fibrinogen on the glycoprotein IIb-IIIa complex of human platelets. Biochem J 1991; 237(Pt 1): 115-120.
22. Shattil SJ, Gao J, Kashiwagi H. Not just anther pretty face: regulation of platelet function at the cytoplasmic face of integrin alpha IIb beta III. Thromb Haemost 1997; 78: 220-225.
23. Dana DH, Carol AW, Susan PK, James DP, Nancy N, Jeffrey WS. A new model of Dual interacting ligand binding site on integrin αIIbβ3 J. Biol. Chem. 1999; 274: 4633-463
24. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-12
25. Honda S, Tomiyama Y, Aoki T, Shiraga M, Kurata Y, Seki J, and Matsuzawa Y. Association between ligand-induce conformational changes of integrin αIIbβ3 and αIIbβ3-mediated intracellular Ca2+ signaling. Blood 1998; 92: 3675-3683.
26. Coller BS, Fotts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation 1989; 80: 1766-1774.
27. Coller BS, Fotts JD, Scudder LE, Smith SR. Antithrombotic effect of monoclonal antibody to the phatelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986; 68: 783-6
28. Weller T, Alig L, Muller MH, Kouns WC, Steiner B. Fibrinogen receptor antagonists: a novel class of promising antithrombotics. Drugs Future 1994; 19: 461-76
29. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists, Thromb Haemost 1995; 74: 302-8
30. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-1696.
31. The EPILOG Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
32. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429-1435.
33. IMPACT Investigators. Randomized placebo-controlled trial effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrin to Minimize Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349: 1422-1428.
34. Brener S, Barr L, Burchenal J, Katz S, George B, Jones A, Cohen E, Gainey P, WhiteH, Cheek H, Moses J, Moliterno D, Effron M and Topol E. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998; 98: 734—741.
35. The EPISTENT Investigators. Randomised placebo-controlled and balloon- angioplasty-controlled trial to assess safety of coronary stenting with use of plate-let glycoprotein-IIb/IIIa blockade. The EPISTENT investigators evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 1998; 352: 87—92.
36. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet receptor inhibition in ischemic syndrome management (PRISM) study investigators. N Engl J Med 1998; 338: 1498—1505.
37. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in pa-tients limited by unstable signs and symptoms (PRISM-PLUS) study investiga-tors. N Engl J Med 1998; 338: 1488—1497.
38. Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E and Gallo L. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion. Haematologica 2001; 86:192-198
39. Tsao PW, Forsythe MS and Mousa SA.Dissociation between the anti-aggregation & anti-secretory effects of platelet integrin αIIbβ3 antagonists, c7E3 and DMP728. Thrombosis Research 1997; 88: 137-146
40. Xiao Z, Theroux P and Frojmovic M. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor. Thrombo Haemost 1999; 81: 281-5
41. Nicholson NS, Panzer-Knodle SG, Salyers AK, Taite BB, Szalony JA,Haas NF, King LW, Zablocki JA, Keller BT, Broschat K, Engleman WV, Herin M, Jacqmin P, Feigen LP. SC-54684A: an orally active inhibitor of platelet aggregation. Circulation 1995; 91:403-410.
42. The SYMPHONY Investigators Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomized trial. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes. Lancet 2000; 355: 337—345.
43. Cannon C, McCabe C, Wilcox R, Langer A, Caspi A, Berink P, Lopez-Sendon J, Toman J, Charlesworth A, Anders R, Alexander J, Skene A and Braunwald E. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102: 149—156.
44. Quinn MJ, Cox D, Foley JB, and Fitzgerald DJ. Glycoprotein IIb/IIIa Receptor Number and Occupancy during Chronic Administration of an Oral Antagonist 1 The journal of pharmacology and experimental therapeutics 2000, 295:670—676
45. Harrington RA, Armstrong PW, Graffagnino C, et al. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. Circulation 2000; 102: 728—35.
46. Cox D, Smith R, Quinn M, Theroux P, Crean P and Fitzgerald DG. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol, 2000; 36: 1514-9.
47. Pratico D, Murphy NP, Fitzgerald DJ. Interaction of a thrombin inhibitor and aplatelet GPIIb/IIIa antagonist in vivo: evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis. J Pharmacol Exp Ther 1997; 281: 1178—85.
48. Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, Salbach P, Kubler W, and Bode C. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors. Blood, 1998; 92: 3240-3249
49. Weber AA and Schror K. Differential inhibition of adenosine diphosphate— versus thrombin receptor—activating peptide—stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics. Blood. 2001; 98: 1619-1621
50. Quinn MJ, Murphy RT, Dooley M, Foley JB, and Fitzgerald DJ. Occupancy of the Internal and External Pools of Glycoprotein IIb/IIIa following Abciximab Bolus and Infusion The Journal of Pharmacology and Experimental Therapeutics 2001; 297: 496—500
51. Tsao PW, Bozarth JM, Jackson SA, Forsythe MS, Flint SK and Mousa SA. Platelet GPIIb/IIIa receptor occupancy studies using a novel fluoresceinated cyclicArg-Gly-Asp peptide. Thromb Res 1995; 77:543—556.
52. Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rudiger S, Taubitz W, Fischer J, Muller I, Meier D, Patscheke H, et al. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors. Thromb Haemostasis 2000; 83: 915—922
53. Nurden P, Humbert M, Piotrowicz RS, Bihour C, Poujol C, Nurden AT and Kunicki TJ. Distribution of ligand-occupied alpha IIb beta 3 in resting and activated human platelets determined by expression of a novel class of ligand-induced binding site recognized by monoclonal antibody AP6. Blood 1996; 88:887—899.
54. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S and Bray PF. Platelet GPIIIa Pl A Polymorphisms Display Different Sensitivities to Agonists. Circulation. 2000; 101: 1013-1018
55. Wang X, Dakshinamurti K, Musat S and Dhalla NS. Pyridoxal 5’-phosphate is an ATP-receptor antagonist in freshly isolated rat cardiomyocytes. J Mol Cell Cardil 1999; 31: 1063-1072
56. Simoons MJ, de Boer MJ, van der Brand MJBM, van Miltenburg AJM, Hoorntje JCA, Heyndrickx GR, van der Wieken LR, De Bono D, Rutsh W, Schaible TF, Weisman HF, Klootwijk P, Stibbe J, de Feyter PJ and the European Cooperative Study Group. Randomized trial of GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603.
57. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therpy. Results of the thrombolysis and angioplasty in myocardial infraction (TAMI) 8 pilot study. J Am Coll Cardiol 1993; 22: 381-389.
58. Muller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/Iia antagonist, and its active prodrug, Lefradafiban, in men. Circulation 1997; 96: 1130-1138.
59. Kereiakes DJ, Kleiman N, Fergusson JJ, Runyon JP, Broderick TM, Higby NA, Martin LH, Hantsbarger G, McDonald S, Anders RJ. Sustained platelet glycoprotein IIb/IIIa blockade with oral Xemolifiban in 170 patients after cornary Stent deployment. Circulation 1997; 96: 1117-1121.
60. Coller VS, Lang D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 1997; 95: 860-867
61. Wagner C, Mace K, Mascelli MA, DeRita R, Lance E, Weisman H, Ghrayeb J, Jordan R. Pharmacodynamics of ReoPro (c7E3 Fab): free plasma levels determine clinical efficacy. Thromb Haemost 1997; S: 7-8. Abstract
62. Riederer MA, Steiner B. The extend of platelet aggregation is dependent on the free GPIIb/IIIa concentration and not the receptor occupancy. Thromb Haemost 1997; S: 6-7. Abstract.
63. Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ. Differential dose-respose to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. Circulation 1996; 94: 906-910.
64. Rival J, Riddle JM, Stein PD. Effects of chronic smoking on platelet function. Thromb Res 1987; 45: 75-85.
65. Umemura K, Kondo K, Ikeda Y, Nakashima M. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban. Thromb Haemost 1997; 78:1381-1384.
66. Coller BS. Monitoring platelet GPIIb/IIIa antagonist therapy. Circulation 1997; 96: 3828-3832.
67. Quinn M, Deering A, Stewart M, Cox D, Foley B, Foley B, Fitzgerald D. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies. Discriminating abciximab and small molecular weight antagonists. Circulation 1999; 99: 2231-2238.
68. He'zard N, Metz D, Nazeyrollas P, Nguyen P, Simon G, Daliphara S, Droulle' C, Elaerts J and Potron G. Free and total platelet glycoprotein IIb/IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA. Thromb Haemost 1999; 81: 869-873.
69. Mak K-H, Kottke-Marchant K, Brooks LM and Topol E. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia. Thromb Haemost 1998; 80: 989-993.
70. Green LJ, Marder P, Um SL, Jakubouski JA and Lawrence JB. Quantitative platelet GPIIb/IIIa receptor antagonist activity using a flow cytometric method. J Clin Lab Anal 1998; 12: 191-196.
71. Tryfiates GP. Vitamin B6 - Metabolism and Role in Growth, Food and Nutrition Press, Westport, CT, 1980; p.365.
72. Gregory JF.Methods of determination of vitamin B6 in food and other biological materials: A critical review. J. Food Comp. Anal. 1988;1: 105-123
73. Trumbo PR and Gregory JF. Metabolic utilization of pyridoxine β-glucoside in rats: Influence of vitamin B6 status and route of administration. J. Nutr. 1988; 118:1336-1342.
74. Dempsey WB and Christensen HN. The specific binding of pyridoxal 5’-phosphate to bovine plasma albumin. J. Biol. Chem. 1962; 237: 1113-1120
75. Mehansho HL and Henderson LM. Transport and accumulation of pyridoxine and pyridoxal by erythrocytes. J. Biol. Chem. 1980; 255: 11901-11907
76. Fasella P. Pyridoxal phosphate. Annual Review Biochemistry 1967; 36: 185-203.
77. Wimmer MS., Sawyer DL and Harrison JH Biphasic inactivation of procine heart mitochondrial malate dehydrogenase by pyridoxal-5’-phosphate. Jounal Biological Chemietry. 1975; 250: 710-715.
78. Gold G. and Widnell CC. Relationship between microsomal membrane permeability and the inhibition of hepatin glucose-6-phosphate by prridoxal phosphate. Jounal Biological Chemietry. 1976; 215: 1035-1041.
79. Ritchey JM, Gibbons I. and Schachman HK. Reactivation of enzymes by light-stimulated cleavage of reduced pyridoxal 5'-phosphate-enzyme complexes. Biochemistry. 1977; 16: 4584-4590.
80. Subbarao J, Kuchibhot la J and Green D. Pyridoxine-induced inhibition of platelet aggregation and the release reaction. Circulation 1977; 56 (pt 3): 77.
81. Van Wyk V, Luus HG and Heyns AD. The in vivo effect in human of pyridoxal-5’-phosphate on platelet function and blood coagulation. Thrombosis Research. 1992; 66: 657-668.
82. Subbarao K, Kakkar V, and Ganguly P. Binding of pyridoxal phosphate to human platelets: its effect on platelet function. Thrombosis Research. 1978; 13: 1017-1029.
83. Subbardo K., Kuchibhotla J. and Kakkar VV. Pyridoxal 5'-phosphate--a new physiological inhibitor of blood coagulation and platelet function. Biochemical Pharmacology. 1979; 28: 531-534.
84. Eger R and Rifkin DB. The preparation and use of pyridoxal [32P] phosphate as a labeling reagent for proteins on the outer surface of membranes. Biochimicaet Biophysica Acta. 1977; 470: 70-83.
85. Cabantchik IZ, Balshin M, Breuer W and Rothstein A. Pyridoxal phosphate. An anionic probe for protein amino groups exposed on the outer and inner surface of intact human red blood cells. J Biol Chem 1975; 250: 5130-5136.
86. Kornecki E and Feinberg H. Pyridoxal phosphate inhibition of platelet function. Am J Physiol 1980; 238: H54-H60.
87. Lam SC, Harfenist EJ, Packham MA and Mustard JF. Investigation of possible mechanism of pyridoxal-5'-phosphate inhibition of platelet reactions. Thromb Res 1980; 20: 633-645.
88. Krishnamurthi S, Westwick J and Kakkar VV. Effect of pyridoxal-5'-phosphate (PALP) on human platelet aggregation, dense granule release and thromboxane B2 generation--role of Schiff base formation. Thromb Haemost 1982; 48: 136-141.
89. Kornecki E and Feinberg H. Mechanism of inhibition of thrombin-induced platelet aggregation by pyridoxal phosphate. Biochemical & Biophysical Research Communications 1979; 90: 963-968.
90. 尤文正,磷酸比哆醛抗血小板凝集機制與GPIIb-IIIa、血小板型態之關係,國立成功大學生物學研究所碩士論文,中華民國八十四年六月。
91. Kornbrot D. Statistical software for microcomputers: SigmaPlot 2000 and SigmaStat2. British Journal of Mathematical and Statistical Psychology 2000; 53: 335-7
92. Heyl D, Luz E, Harris SA and Folkers K. Phosphates of the vitamin B6 group. 1. The structure of codecarboxylase. J. Am. Chem. Soc. 1951; 73: 3430
93. 陳銘鴻,磷酸根對維生素B6與胺基間Schiff base形成之影響,屏東科技大學食品科學系研究所碩士論文,中華民國八十九年六月。
94. Springer TA. Folding of the N-terminal, ligand-binding region of integrin α-subunits into a β-propeller domain. Proc Natl Acad Sci USA 1997; 94: 65
95. Tozer EC, Liddington RC, Sutcliffe MJ, Smeeton AH, Loftus JC: Ligand binding to integrin αIIbβ3 is dependent on a MIDAS-like domain in the β3 subunit. J Biol Chem 1996; 271: 21978

QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top